Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk

Quince Therapeutics ( (QNCX) ) has shared an announcement.

On April 27, 2026, Quince Therapeutics said it had regained compliance with Nasdaq’s minimum bid price requirement after its shares closed at or above $1.00 for 10 consecutive business days from April 13 through April 24, 2026, leading Nasdaq to close the bid-price compliance matter. However, the company remains out of compliance with Nasdaq’s $50 million market value of listed securities requirement and has until September 14, 2026, to restore its valuation, leaving ongoing uncertainty around its continued listing status and posing a lingering risk for shareholders.

The most recent analyst rating on (QNCX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.

Spark’s Take on QNCX Stock

According to Spark, TipRanks’ AI Analyst, QNCX is a Neutral.

The score is driven primarily by very weak financial performance (no revenue, widening losses, accelerating cash burn, and negative equity), with technicals also signaling bearish momentum despite some oversold readings. Valuation offers limited support due to ongoing losses, and corporate events add meaningful risk from Nasdaq compliance issues and restructuring uncertainty (partly offset by EIB debt elimination).

To see Spark’s full report on QNCX stock, click here.

More about Quince Therapeutics

Quince Therapeutics, Inc. operates in the biopharmaceutical sector, focusing on the development of therapeutic products. Its common stock is listed on the Nasdaq Global Select Market, where it must meet ongoing quantitative listing standards, including minimum bid price and market value thresholds that are closely watched by investors and regulators.

Average Trading Volume: 10,679,662

Technical Sentiment Signal: Sell

Current Market Cap: $22.17M

For a thorough assessment of QNCX stock, go to TipRanks’ Stock Analysis page.